ArticleCancer discovery2017
The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 73 citations in OpenAlex.
- N6-methyladenosine modification of FZR1 mRNA positively regulates antiviral innate immunity by targeting the MAVS-TRAF3/6 axis.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Genetic analysis of three familial cases of pure terminal 19p13.3 duplication caused by maternal balanced translocation t(19;21) (p13.3;p12).Frontiers in genetics · 2026Article
- Targeting ubiquitination in disease and therapy.Signal transduction and targeted therapy · 2025Review
- Research advancements regarding the relationship between FBXO2 and malignant tumors (Review).Molecular medicine reports · 2025Review
- Nutrient restriction protects against valve interstitial cell calcification by upregulating ubiquitin mediated proteolysis.Frontiers in cardiovascular medicine · 2025Article
- Pin1-catalyzed conformational regulation after phosphorylation: A distinct checkpoint in cell signaling and drug discovery.Science signaling · 2024Review
- Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy.Leukemia · 2024Article
- Reciprocal antagonism of PIN1-APC/CNature communications · 2024Article
- RNF43 Inactivation Enhances the B-RAF/MEK Signaling and Creates a Combinatory Therapeutic Target in Cancer Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Deletion of a core APC/C component reveals APC/C function in regulating neuronal USP1 levels and morphology.Frontiers in molecular neuroscience · 2024Article
- Article
- Deficiency of BAP1 inhibits neuroblastoma tumorigenesis through destabilization of MYCN.Cell death & disease · 2023Article
- Targeting the anaphase-promoting complex/cyclosome (APC/C) enhanced antiproliferative and apoptotic response in bladder cancer.Saudi journal of biological sciences · 2023Article
- Insights into the aberrant CDK4/6 signaling pathway as a therapeutic target in tumorigenesis.Advances in protein chemistry and structural biology · 2023Review
- FBXO43 increases CCND1 stability to promote hepatocellular carcinoma cell proliferation and migration.Frontiers in oncology · 2023Article
- Insufficiency of FZR1 disturbs HSC quiescence by inhibiting ubiquitin-dependent degradation of RUNX1 in aplastic anemia.Leukemia · 2022Article
- Acetylation-dependent regulation of BRAF oncogenic function.Cell reports · 2022Article
- E3 ubiquitin ligases: styles, structures and functions.Molecular biomedicine · 2021Review
- Identification of Systems Level Molecular Signatures from Glioblastoma Multiforme Derived Extracellular Vesicles.Journal of molecular neuroscience : MN · 2021Article
- Review
Corrections and comments
- Commented on by
Authors and funding
22 authors at 1 institution in 1 country.
Lixin WanDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. wwei2@bidmc.harvard.edu lixin.wan@moffitt.org caojuxi@gmail.com rutaocui@bu.edu ppandolf@bidmc.harvard.edu.
Ming ChenCancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Juxiang CaoDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts. wwei2@bidmc.harvard.edu lixin.wan@moffitt.org caojuxi@gmail.com rutaocui@bu.edu ppandolf@bidmc.harvard.edu.
Xiangpeng DaiDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Qing YinDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Jinfang ZhangDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Su-Jung SongCancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Ying LuDepartment of Systems Biology, Harvard Medical School, Boston, Massachusetts.
Jing LiuDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Hiroyuki InuzukaDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Jesse M KatonCancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Kelsey BerryCancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Jacqueline FungCancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Christopher NgCancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Pengda LiuDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Min Sup SongDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lian XueDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Roderick T BronsonDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts.
Marc W KirschnerDepartment of Systems Biology, Harvard Medical School, Boston, Massachusetts.
Rutao CuiDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts. wwei2@bidmc.harvard.edu lixin.wan@moffitt.org caojuxi@gmail.com rutaocui@bu.edu ppandolf@bidmc.harvard.edu.
Pier Paolo PandolfiCancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. wwei2@bidmc.harvard.edu lixin.wan@moffitt.org caojuxi@gmail.com rutaocui@bu.edu ppandolf@bidmc.harvard.edu.
Wenyi WeiDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. wwei2@bidmc.harvard.edu lixin.wan@moffitt.org caojuxi@gmail.com rutaocui@bu.edu ppandolf@bidmc.harvard.edu.
Harvard University · US
Funding
CELL CYCLE REGULATIONR01GM039023 · NIGMS · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI KIRSCHNER, MARC WALLACE · 1988 to 2017
$10.2MTissue, Pathology and BioinformaticsP50CA168536 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SMALLEY, KEIRAN · 2013 to 2017
$8.5MNovel regulation of PI3K/Akt to direct targeted breast cancer therapiesR01CA177910 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WEI, WENYI · 2013 to 2023
$3.9MInterplay between Cdh1 and major regulatory pathways in human cancerR01GM089763 · NIGMS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WEI, WENYI · 2009 to 2018
$3.0MCharacterizing the signaling pathways that regulate Skp2 oncogenic functionR01CA200573 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WEI, WENYI · 2016 to 2020
$2.0MTargeting the APC/Cdc20 E3 ubiquitin ligase for chemoradiation sensitizationR01CA200651 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WEI, WENYI · 2016 to 2020
$1.9MFunctional analysis of beta-TRCP in cell cycle control and DNA damage responseR01GM094777 · NIGMS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WEI, WENYI · 2012 to 2015
$1.3MElucidating a Novel Akt Activation Mechanism for Targeted Prostate Cancer TherapyR00CA181342 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LIU, PENGDA · 2016 to 2018
$653kA Novel Oncogenic Role for Cdc20 Implications in Adult T Cell Leukemia TreatmentR00CA183914 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI WAN, LIXIN · 2016 to 2018
$652kNew insights into the role of the Fbw7 tumor suppressor in senescence and agingK01AG041218 · NIA · BETH ISRAEL DEACONESS MEDICAL CENTER · PI INUZUKA, HIROYUKI · 2011 to 2015
$621kA Novel Oncogenic Role for Cdc20 Implications in Adult T Cell Leukemia TreatmentK99CA183914 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WAN, LIXIN · 2014 to 2015
$339kNCI NIH HHS K99 CA183914NCI NIH HHS P50 CA168536NCI NIH HHS R00 CA181342NCI NIH HHS R00 CA183914NCI NIH HHS R01 CA177910NCI NIH HHS R01 CA200573NCI NIH HHS R01 CA200651NIA NIH HHS K01 AG041218NIGMS NIH HHS R01 GM039023NIGMS NIH HHS R01 GM089763NIGMS NIH HHS R01 GM094777
Abstract
BRAF drives tumorigenesis by coordinating the activation of the RAS/RAF/MEK/ERK oncogenic signaling cascade. However, upstream pathways governing BRAF kinase activity and protein stability remain undefined. Here, we report that in primary cells with active APC
Indexed as
Adenomatous Polyposis Coli ProteinAnimalsCarcinogenesisCdh1 ProteinsCell Line, TumorCyclin D1DimerizationHeLa CellsHumansMelanocytesMelanomaMiceMultiprotein ComplexesPhosphorylationProtein Kinase InhibitorsProto-Oncogene Proteins B-rafAdenomatous Polyposis Coli ProteinAPC protein, humanBRAF protein, humanCdh1 ProteinsCyclin D1FZR1 protein, humanMultiprotein ComplexesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafUbiquitin-Protein Ligases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.